The current earnings forecast score of LifeVantage Corp is 7.00, ranking 112 out of 155 in the Pharmaceuticals industry. The average price target is 14.50, with a high of 17.00 and a low of 12.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
7.000
Target Price
+9.89%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
LifeVantage Corp
LFVN
2
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
34
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is LifeVantage Corp's expected revenue for the next quarter?
LifeVantage Corp's expected revenue is 45.95M.
What is LifeVantage Corp's price target?
Analysts forecast that LifeVantage Corp's price target is USD 14.50, with the highest forecast at USD 17.00 and the lowest forecast at USD 12.00.
How have LifeVantage CorpLFVN's recent earnings per share performed?
The market expectation was USD 0.11, while LifeVantage CorpLFVN's earnings per share (EPS) for the previous quarter was USD 0.02. EPS for the next quarter is expected at USD 0.13.
What is the analyst rating for LifeVantage Corp?
Based on the ratings of LifeVantage Corp's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.